Biogen Alzheimer - Search News

Alzheimer's, Biogen and european commission

MarketWatch on MSN · 20h

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.

Reuters on MSN · 19h

EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with early Alzheimer's disease, reversing its initial decision from four months ago.

The Associated Press - Busines… · 20h

European committee takes a second look at Alzheimer’s drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.

Pharmalittle: We’re reading about an Alzheimer’s drug about-face, Bavarian Nordic’s views on Trump, and more

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

Zacks.com on MSN1h

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

14h

Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

27m

Cautious Optimism for Biogen: Hold Rating Amidst European Approval Developments

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results